BIOHM, a premier microbiome company directed by Dr. Mahmoud Ghannoum’s cutting-edge technology, announced a $7.5 million equity fundraising. Middleland Capital’s VTC Ventures led the round, with participation from Felton Group, LLC, Jobs Ohio Growth Capital Fund, Aztec Capital Management LLC, Cleveland Life Science Advisors, Valley Growth Ventures, LLC, Jump Start, Inc., and other investors. The funding will allow BIOHM to maintain its position as a data-driven, cutting-edge microbiome innovation partner for consumers, physicians, and food, beverage, and dietary supplement companies.
BIOHM was the first to address the important relationship between fungi and bacteria in gut health, using cutting-edge technology and one of the world’s largest microbiome datasets that integrates bacterial and fungal sequencing.
BIOHM has increased its involvement with some of the world’s major ingredient companies in the previous year to provide a world-class package of services, including product creation using its industry-leading database, bioinformatics, testing, and clinical trial support. Furthermore, BIOHM is now launching a clinical extension for medical practitioners and is rapidly growing into shops across the country.
BIOHM not only handles one of the most extensive gut health datasets, but it also has access to one of the largest collections of fungal strains, second only to the CDC (CDC).
Dr. Ghannoum, BIOHM’s co-founder, is a world-renowned microbiome researcher who is best known for coining the term “mycobiome” (the body’s fungus community). With over 500 papers and work that has been mentioned over 30,000 times, he is one of the top 0.5% of cited microbiologists — and one of the top 2% of all scientists across all disciplines. Dr. Ghannoum has been consistently sponsored by the National Institutes of Health (NIH) since 1991, with his most recent NIH funding coming at the age of 72.
BIOHM is one of the world’s leading microbiome companies utilizing microbiome data to create powerful new products and ingredients to help individuals live healthier lives. Our first BIOHM FX probiotic supplement was designed to specifically help reduce digestive plaque found in the gut. We have since expanded our line of microbiome data-powered products to include more probiotic and prebiotic supplements, as well as a personalized Gut Test.
Managed by Middleland Capital, VTC Ventures is a private investment fund focused on life science and food/agriculture technology opportunities across the Commonwealth of Virginia and opportunities outside Virginia with a connection to Virginia Tech or Carilion Clinic. VTC Ventures aims to partner with exceptional management teams to commercialize innovative technologies, accelerate growth, and build long-term value.
